Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILUVIEN in Paediatric Non-infectious Posterior Uveitis
2023-509469-19-00Phase 4Authorised
- Sponsor
- Alimera Sciences
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of fluocinolone in Posterior uveitis (non-infectious), sponsored by Alimera Sciences. Primary endpoints: Treatment success based on absence of cystoid macular oedema and improvement in vitreous haze, Rate of cataract formation and 1 more. Planned start Jun 2024; status: authorised.
02
Drugs
fluocinolone
03
Conditions
Posterior uveitis (non-infectious)
Beyond the preview
Go deeper on 2023-509469-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509469-19-00.